Considerations in the Development of Drugs to Treat Sarcopenia
The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Abstract
Sarcopenia describes reduced skeletal muscle mass and impaired muscle function associated with aging and with a variety of chronic diseases prevalent in the aging population. With increasing understanding of the molecular pathways participating in the structural and functional changes affecting skeletal muscle in these conditions, a number of potential targets for pharmacological interventions to reverse sarcopenia have been identified. The clinical evaluation of therapeutic candidates directed at these targets will require that the efficacy and safety of the drug candidates be adequately evaluated to meet the regulatory standards of the Food and Drug Administration (FDA). Concerns unique to drug development may require different approaches to clinical study design than have been used in the epidemiological research that identified the clinical need for these programs and the intervention trials conducted to date. In addition to being responsive to clinical need as perceived by patients and physicians, clinical trial data must demonstrate to the FDA that the drug provides an objective and clinically meaningful advantage, and must demonstrate to all involved in healthcare decision‐making that its benefits justify the associated costs and risks. Potential primary efficacy endpoints for trials of a drug for treatment of sarcopenia include physical performance, falls, fractures, and patient‐reported outcomes assessing function and quality of life. Each potential endpoint has advantages and disadvantages from scientific, clinical, and regulatory perspectives that must be carefully considered in the design of trials for sarcopenia treatments.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Abellan Van Kan, G., Rolland, Y., Andrieu, S., Bauer, J., Beauchet, O., Bonnefoy, M., Cesari, M., Donini, L. M., Gillette-Guyonnet, S., Inzitari, M., et al. (2009) · The Journal of nutrition, health and aging · doi:10.1007/s12603-009-0246-z · Cited by 2,003
Muscle weakness and falls in older adults: a systematic review and meta-analysis
Moreland, J. D., Richardson, J. A., Goldsmith, C. H., & Clase, C. M. (2004) · Journal of the American Geriatrics Society · doi:10.1111/j.1532-5415.2004.52310.x · Cited by 988
Cawthon, P. M., Fox, K. M., Gandra, S. R., Delmonico, M. J., Chiou, C., Anthony, M. S., Sewall, A., Goodpaster, B., Satterfield, S., Cummings, S. R., et al. (2009) · Journal of the American Geriatrics Society · doi:10.1111/j.1532-5415.2009.02366.x · Cited by 414
Skeletal muscle and mortality results from the InCHIANTI study
Cesari, M., Pahor, M., Lauretani, F., Zamboni, V., Bandinelli, S., Bernabei, R., Guralnik, J. M., & Ferrucci, L. (2009) · The Journals of Gerontology Series A: Biological Sciences and Medical Sciences · doi:10.1093/gerona/gln031 · Cited by 346 · cited 1×
“fractures,(8) development of mobility impairment,(9) and mortality.(10) As a result, there has been a shift of emphasis toward defining sarcopenia in terms of functional characteristics of skeletal muscle, such as strength, or as integrated function assessed using tests of physical performance, rather than measures of…”
Background
Cited by
Mitochondrial dysfunction and sarcopenia of aging: from signaling pathways to clinical trials
Marzetti, E., Calvani, R., Cesari, M., Buford, T. W., Lorenzi, M., Behnke, B. J., & Leeuwenburgh, C. (2013) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2013.06.024 · Cited by 627
Chronic low-grade inflammation and age-related sarcopenia
Beyer, I., Mets, T., & Bautmans, I. (2012) · Current Opinion in Clinical Nutrition and Metabolic Care · doi:10.1097/mco.0b013e32834dd297 · Cited by 400
New horizons in the pathogenesis, diagnosis and management of sarcopenia
Sayer, A. A., Robinson, S. M., Patel, H. P., Shavlakadze, T., Cooper, C., & Grounds, M. D. (2013) · Age and Ageing · doi:10.1093/ageing/afs191 · Cited by 290
Sarcopenia in the elderly: Diagnosis, physiopathology and treatment
Malafarina, V., Úriz-Otano, F., Iniesta, R., & Gil-Guerrero, L. (2012) · Maturitas · doi:10.1016/j.maturitas.2011.11.012 · Cited by 297
Fragala, M. S., Kenny, A. M., & Kuchel, G. A. (2015) · Sports Medicine · doi:10.1007/s40279-015-0305-z · Cited by 246
“Nevertheless, with the increased understanding of the pathways contributing to sarcopenia and muscle quality, several potential targets for drug development have been identified [194].”
Background
Metadata
- Authors
- Brass, E. P., & Sietsema, K. E.
- Venue
- Journal of the American Geriatrics Society
- Publisher
- Wiley
- Published
- 2011-03
- Volume
- 59
- Issue
- 3
- Pages
- 530-535
- ISSN
- 0002-8614 (ISSN-L)
- 1532-5415
- OpenAlex
- W1540752626
- Cited by
- 31
- References
- 4
- FWCI
- 2.70
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Considerations in the Development of Drugs to Treat Sarcopenia. https://app.cochat.ai/papers/10.1111/j.1532-5415.2010.03285.x
- The paper
- Brass, E. P., & Sietsema, K. E. (2011). Considerations in the Development of Drugs to Treat Sarcopenia. Journal of the American Geriatrics Society. https://doi.org/10.1111/j.1532-5415.2010.03285.x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.